Regulation of the hypothalamic-pituitary-adrenal axis

NeuroImmunoModulation

Volumn 16, Issue 5, 2009, Pages 265-271

  Papadimitriou, Anastasios ^a   Priftis, Kostas N ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b PENTELI CHILDREN S HOSPITAL   (Greece)

Author keywords

Adrenals; Adrenocorticotropic hormone; Arginine vasopressin; Corticotropin releasing hormone; Glucocorticoids; Hypothalamus; Pituitary

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; HYDROCORTISONE; MELANOCORTIN 2 RECEPTOR; PROOPIOMELANOCORTIN; VASOPRESSIN V1B RECEPTOR;

ACTH SECRETING CELL; ADENOHYPOPHYSIS; ADRENAL CORTEX; CIRCADIAN RHYTHM; DIFFUSION; EMOTIONAL STRESS; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE RELEASE; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MEDIAN EMINENCE; PHYSICAL STRESS; PRIORITY JOURNAL; REVIEW; STEROIDOGENESIS; STRESS MANAGEMENT; SYSTEMIC CIRCULATION; THALAMUS MIDLINE NUCLEUS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRESS, PHYSIOLOGICAL;

EID: 67651093961     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000216184     Document Type: Review

References (49)

1. Miller WL: StAR search - what we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import. Mol Endocrinol 2007;21:589-601.
2. Payne AH, Hales DB: Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-970.
3. Habib KE, Gold PW, Chrousos GP: Neuro-endocrinology of stress. Endocrinol Metab Clin North Am 2001;30: 695-728.
4. Selye H: A syndrome produced by diverse nocuous agents. Nature 1936;138:32-36.
5. McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
6. Chrousos GP, Gold PW: The concepts of stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-1252.
7. Munck A, Guyre PM, Holbrook NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
8. Munck A, Náray-Fejes-Tóth A: The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol Cell Endocrinol 1992;90:C1-C4.
9. Chrousos GP: The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 2000;917:38-67.
10. Fuller RW: The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 1992;13:250-270.
11. Calogero AE, Gallucci WT, Chrousos GP, Gold PW: Interaction between GABAergic neurotransmission and rat hypothalamic CRH in vitro. Brain Res 1988;463: 28-36.
12. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 2004;332: 1351-1362.
13. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981;213:1394-1397.
14. Majzoub JA: Corticotropin-releasing hormone physiology. Eur J Endocrinol 2006;155(suppl 1):71-76.
15. Borrelli E: A chilled-out knockout. Nat Genet 1998;19:108-109.
16. Chen R, Lewis KA, Perrin MH, Vale WW: Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993;90: 8967-8971.
17. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836-840.
18. Hillhouse EW, Grammatopoulos DK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006;27: 260-286.
19. Kostich WA, Chen A, Sperle K, Largent BL: Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2γreceptor. Mol Endocrinol 1998;12:1077-1085.
20. Martinez V, Wang L, Million M, Rivier J, Tache Y: Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 2004;25:1733-1744.
21. Li C, Vaughan J, Sawchenko PE, Vale WW: Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 2002;22: 991-1001.
22. Kuperman Y, Chen A: Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab 2008;19: 122-129.
23. Suda T, Kageyama K, Sakihara S, Nigawara T: Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 2004;25: 1689-1701.
24. Woods RJ, Grossman A, Saphier P, Kennedy K, Ur E, Behan D, Potter E, Vale W, Lowry PJ: Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. J Clin Endocrinol Metab 1994;78: 73-76.
25. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J: A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001;104: 849-859.
26. Lamberts SW, Verleun T, Oosterom R, de Jong F, Hackeng WH: Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J Clin Endocrinol Metab 1984;58: 298-303.
27. Legros JJ, Chiodera P, Demey-Ponsart E: Inhibitory influence of exogenous oxytocin on adrenocorticotropin secretion in normal human subjects. J Clin Endocrinol Metab 1982;55: 1035-1039.
28. Taylor T, Dluhy RG, Williams GH: fS-Endor-phin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab 1983;57:592-596.
29. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U: Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007;148: 1574-1581.
30. Alexander LD, Evans K, Sander LD: A possible involvement of VIP in feeding-induced secretion of ACTH and corticosterone in the rat. Physiol Behav 1995;58: 409-413.
31. Alexander LD, Sander LD: Involvement of vasopressin and corticotropin-releasing hormone in VIP- and PHI-induced secretion of ACTH and corticosterone. Neuropeptides 1995;28: 167-173.
32. 1 -adrenoceptors in humans stimulates secretion of prolactin and TSH, as well as ACTH. Am J Physiol 1993;264:E208-E214.
33. Korbonits M, Kaltsas G, Perry LA, Grossman AB, Monson JP, Besser GM, Trainer PJ: Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clin Endocrinol (Oxf) 1999;51: 369-375.
34. Korbonits M, Kaltsas G, Perry LA, Putigna-no P, Grossman AB, Besser GM, Trainer PJ: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999;84: 2489-2495.
35. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG: Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 2006;58: 46-57.
36. Besedovsky HO, del Rey A: Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996;17: 64-102.
37. Ray DW, Ren SG, Melmed S: Leukemia inhibitory factor stimulates proopiomelanocortin expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996;97: 1852-1859.
38. Young EA, Carlson NE, Brown MB: 24-Hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology 2001;25:267-276.
39. Getting SJ: Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006;111:1-15.
40. 2+ channels are required for adrenocorticotropin-stimulated cortisol production by bovine adrenal zona fasciculata cells. Mol Endocrinol 1993;7:1031-1040.
41. Munari-Silem Y, Lebrethon MC, Morand I, Rousset B, Saez JM: Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. J Clin Invest 1995;95: 1429-1439.
42. Bose HS, Sugawara T, Strauss JF 3rd, Miller WL: The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 1996;335: 1870-1878.
43. Blondet A, Doghman M, Penhoat A, Durand P, Bégeot M, Naville D: The human MC2-R gene expression: different aspects of its control. Endocr Res 2002;28:275-280.
44. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA: The dominant negative activity of the human glucocorticoid receptor β-isoform. Specificity and mechanisms of action. J Biol Chem 1999;274: 27857-27866.
45. Chrousos GP, Kino T: Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007;10:213-219.
46. Buckingham JC: Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006;147(suppl 1):S258-S268.
47. Keller-Wood ME, Dallman MF: Corticosteroid inhibition of ACTH secretion. Endocr Rev 1984;5:1-24.
48. Tasker JG, Di S, Malcher-Lopes R: Rapid glucocorticoid signaling via membrane-associated receptors. Endocrinolog y 2006;147: 5549-5556.
49. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG: Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and 7-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005;146: 4292-4301.